Ann: NYR-BI03 Phase Ia Clinical Trial Update - Correction, page-41

So the 2 posters that don’t hold a share, have been downramping by posting up failed biotechs with no relationship to what NYR is and one poster that has lost a ton of money in the past and is salty about his loss so hangs around and posts when the stock pulls back but disappears when the stock goes up and the other that lost money it seems from another poster and has been downramping for months and calling the death of the company when it went to 5 cents and then disappeared when it went to 15 cents.

So investors should listen to two salty investors and the 4 million dollars institutions, directors and investors invested at 12 cents 1 month ago are just donkeys lol. Company has spent 6 years proving the drug over multiple fronts and the only drug in the world first in class to treat primary, secondary brain injury and cardiovascular protection which betters any current FDA drug, cashed up now and has a runway all they way through safety and partnerships with the US Army for future non dilutive funding. Bought more Zecs yesterday. Will still become a 100 million dollar plus market cap like its peers in the same space on safety clearence coming up